EMBC News and Press, Embecta Corp. From 08/15/22

PARSIPPANY, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company (“BD”), today reported financi...

PARSIPPANY, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (NASDAQ: EMBC), one of the largest pure-play diabetes care companies, announced today that its Board of Directors declared a quarterly cash dividend of $0.15 for each issued and outstanding share of ...

Yacktman's 13F equity portfolio value decreased from $11.21B to $9.64B this quarter. Yacktman Asset Management added Warner Bros. Discovery and Embecta Corp. while decreasing Sysco Corporation and Coca-Cola Company. Yacktman’s largest five stakes are at ~31% of the portfoli...

PARSIPPANY, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (NASDAQ: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today announced that it will report ...

Embecta has a history of profitability, a strong base of revenues, and good free cash flow generation. Diabetes is a large market whose patients are obliged to use insulin for the rest of their lives. This provides a lot of support for the company’s economics. Embectaȁ...

Embecta Corp. (EMBC) Q2 2022 Results Earnings Conference Call May 13, 2022, 08:00 AM ET Company Participants Devdatt Kurdikar - President and Chief Executive Officer Jake Elguicze - Senior Vice President and Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Securities...

The following slide deck was published by Embecta Corp. in conjunction with their 2022 Q2 earnings call. For further details see: Embecta Corp. 2022 Q2 - Results - Earnings Call Presentation

Gainers: Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. SomaLogic (SLGC) +19%. Veru (VERU) +18%. Celularity (CELU) +17%. Losers: Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%. Embecta (EMBC) -7%. Wave Life Sciences (WVE) -5%. ...

Embecta press release (NASDAQ:EMBC): Q2 GAAP EPS of $1.38. Revenue of $274.5M (-3.4% Y/Y). For further details see: Embecta GAAP EPS of $1.38, revenue of $274.5M

PARSIPPANY, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today reported financial results for ...